UDN Phase II Funding Opportunities: Frequently Asked Questions

Choose a RFA below for FAQs specific to that funding opportunity:

Clinical Sites for the Undiagnosed Diseases Network (UDN) Phase II (U01) (RFA-RM-17-019)

1) Will Clinical Site applicants be able to read the current UDN protocol?

2) The “Funds Available and Anticipated Number of Awards” budget does not seem to match with the “Award Budget”?

3) Do direct costs include consortium F&A costs requested by a subcontract?

4) Can a PD/PI on a Clinical Site application also be on a different UDN Phase II application (Coordinating Center, Metabolomics Core, Model Organisms Screening Center, or Sequencing Core) in a role other than PD/PI?

5) Who can be the PD/PI of a Clinical Site application if the institution is submitting an application for a different UDN Phase II award (Coordinating Center, Metabolomics Core, Model Organisms Screening Center, or Sequencing Core)?

6) If submitting a multi-PI application, does each PD/PI need to be well-established in clinical research?

7) What is expected in a letter of support to document institutional commitment to sustaining the program beyond NIH Common Fund support?

Coordinating Center for the Undiagnosed Diseases Network (UDN) Phase II (U01) (RFA-RM-17-018)

1) Will Coordinating Center applicants be able to read the current UDN protocol?

2) The “Funds Available and Anticipated Number of Awards” budget does not seem to match with the “Award Budget”?

3) Do direct costs include consortium F&A costs requested by a subcontract?

4) Can a PD/PI on a Coordinating Center application also be on a different UDN Phase II application (Clinical Site, Metabolomics Core, Model Organisms Screening Center, or Sequencing Core) in a role other than PD/PI?

5) Who can be the PD/PI of a Coordinating Center application if the institution is submitting an application for a different UDN Phase II award (Clinical Site, Metabolomics Core, Model Organisms Screening Center, or Sequencing Core)?

6) If submitting a multi-PI application, does each PD/PI need to be well-established in clinical research?

7) What is expected in a letter of support to document institutional commitment to sustaining the program beyond NIH Common Fund support?

Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54) (RFA-RM-17-017)

1) Will Model Organisms Screening Center applicants be able to read the current UDN protocol?

2) The “Funds Available and Anticipated Number of Awards” budget does not seem to match with the “Award Budget”?

3) Do direct costs include consortium F&A costs requested by a subcontract?

4) Is the FY21 budget really $4350K direct costs?

5) Can a PD/PI on a Model Organisms Screening Center application also be on a different UDN Phase II application (Clinical Site, Coordinating Center, Metabolomics Core, or Sequencing Core) in a role other than PD/PI?

6) Who can be the PD/PI of a Model Organisms Screening Center application if the institution is submitting an application for a different UDN Phase II award (Clinical Site, Coordinating Center, Metabolomics Core, or Sequencing Core)?

7) What is expected in a letter of support to document institutional commitment to sustaining the program beyond NIH Common Fund support?

8) What are the top NIH priorities for awarding a Model Organisms Screening Center?

9) How will the UDN assign gene variants to the Model Organisms Screening Center?

10) The Model Organisms Screening Center is anticipated to evaluate approximately 200 gene variants each year. Will the 200 gene variants involve 200 different UDN participants or multiple variants for each participant?

11) For candidate variants, will the Model Organisms Screening Center have access to clinical/phenotypic information and the full sequencing data from the respective UDN participants?

12) Does each variant assigned to the Model Organisms Screening Center require screening and analysis using all model organisms available to the Center? For example, does the FOA require analysis of all variants in both Drosophila and zebrafish models?

13) Do all assigned gene variants require analysis using wet-lab approaches (i.e., in a model organism or cell-based assay)?

14) Does the FOA require each Model Organism Screening Center application to have the capacity to analyze variants in both Drosophila and zebrafish models?

15) In addition to Drosophila and zebrafish, does the FOA invite other model organisms or cell-based assays?

16) Is the Model Organisms Screening Center expected to confirm or rule out definitively the pathogenicity of all gene variants assigned to the Center?

Sequencing Core(s) for the Undiagnosed Diseases Network (UDN) Phase II (U01) (RFA-RM-17-016)

1) Will Sequencing Core applicants be able to read the current UDN protocol?

2) The “Funds Available and Anticipated Number of Awards” budget does not seem to match with the “Award Budget”?

3) Do direct costs include consortium F&A costs requested by a subcontract?

4) Can a PD/PI on a Sequencing Core application also be on a different UDN Phase II application (Clinical Site, Coordinating Center, Metabolomics Core, or Model Organisms Screening Center) in a role other than PD/PI?

5) Who can be the PD/PI of a Sequencing Core application if the institution is submitting an application for a different UDN Phase II award (Clinical Site, Coordinating Center, Metabolomics Core, or Model Organisms Screening Center)?

6) If submitting a multi-PI application, does each PD/PI need to be well-established in sequencing?

7) What is expected in a letter of support to document institutional commitment to sustaining the program beyond NIH Common Fund support?

8) When does the two-week timeframe for return of raw (unassembled) sequence data start and stop?

9) Will the UDN DNA Sequencing Core need to provide DNA extraction?

10) What does re-analysis mean for previously sequenced exomes and genomes?

11) What does re-interpretation mean?

12) How should we budget for additional research sequencing approaches such as RNAseq, ChIP-seq, etc?

Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01) (RFA-RM-17-015)

1) Will Metabolomics Core applicants be able to read the current UDN protocol?

2) The “Funds Available and Anticipated Number of Awards” budget does not seem to match with the “Award Budget”?

3) Do direct costs include consortium F&A costs requested by a subcontract?

4) Can a PD/PI on a Metabolomics Core application also be on a different UDN Phase II application (Clinical Site, Coordinating Center, Model Organisms Screening Center, or Sequencing Core) in a role other than PD/PI?

5) Who can be the PD/PI of a Metabolomics Core application if the institution is submitting an application for a different UDN Phase II award (Clinical Site, Coordinating Center, Model Organisms Screening Center, or Sequencing Core)?

6) If submitting a multi-PI application, does each PD/PI need to be well-established in metabolomics analysis?

7) What is expected in a letter of support to document institutional commitment to sustaining the program beyond NIH Common Fund support?

8) Are letters of support from all alternate sites with special expertise necessary?

9) For UDN participant sample workup, will the Metabolomics Core have access to clinical and phenotypic information and the full sequencing data from the respective participants?

10) Does the Metabolomics Core need to budget for cases referred to alternate sites with special expertise? Is billing to the Clinical Site or participant allowed?

 

This page last reviewed on September 11, 2017